Comparative Pharmacology
Head-to-head clinical analysis: 8 MOP versus OXSORALEN ULTRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: 8 MOP versus OXSORALEN ULTRA.
8-MOP vs OXSORALEN-ULTRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
8-MOP (methoxsalen) is a psoralen compound that intercalates into DNA. Upon UVA irradiation, it forms covalent cross-links between pyrimidine bases, inhibiting DNA synthesis and cell division. It also reduces the proliferation of epidermal cells and suppresses cutaneous immune responses by inhibiting antigen presentation and cytokine release.
Oxsoralen-Ultra (methoxsalen) is a psoralen derivative that, upon photoactivation by UVA radiation, forms covalent cross-links with DNA, thereby inhibiting DNA synthesis and cell division. It also suppresses cutaneous immune responses and reduces epidermal cell turnover.
Psoriasis: 0.4–0.6 mg/kg orally 2 hours before UVA exposure, 2–3 times per week. Vitiligo: 20 mg (0.3–0.4 mg/kg) 2 hours before UVA. Dose adjusted based on skin type and UVA dose.
0.6 mg/kg orally as a single dose 2 hours prior to PUVA therapy, administered 3 times per week on non-consecutive days.
None Documented
None Documented
Terminal elimination half-life is 1–2 hours; however, clinical effect persists longer due to sustained phototoxic reaction.
2 hours (terminal) with clinical context: elimination is rapid; no accumulation with q3-5d dosing.
Renal excretion of metabolites (~95%) with <0.5% unchanged; biliary/fecal elimination ~5%.
Primarily renal: 90-95% as metabolites within 24 hours; minimal biliary/fecal (<5%).
Category C
Category C
Psoralen
Psoralen